SHIRE IN-LICENSES DEVELOPMENT RIGHTS TO TISSUE PROTECTIVE CYTOKINE TECHNOLOGY FROM WARREN PHARMACEUTICALS

Shire plc announces that it has in-licensed rights to tissue protective cytokine (TPC) technology under an agreement with Warren Pharmaceuticals, Inc. The agreement gives Shire exclusive worldwide rights to develop TPCs in non-Nervous System indications, including renal and genetic disease areas.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-03-2006/0004444132&EDATE=)